Head of center Jørgen Kjems, from the Center of Excellence CellPat at Aarhus University, is at the forefront of one of the five new research projects from the Open Discovery Innovation Network (ODIN) addressing five global health problems. In this project Professor Kjems and the rest of the research team from Aarhus University will collaborate with the pharmaceutical industry to generate new knowledge as well as new tools that can be used to develop new drugs.
The Open Discovery Innovation Network (ODIN) aims to address five global health problems: kidney diseases, atherosclerosis, colon cancer, non-alcoholic fatty liver disease, and neurological disorders. Head of center Jørgen Kjems, from the DNRF’s Center for Cellular Signal Patterns (CellPat) at Aarhus University, is at the forefront of one of these five innovative projects.
In this project Professor Kjems and the researchers from Aarhus University will collaborate with the pharmaceutical industry to generate new knowledge and new tools that can be used to develop new drugs. The Novo Nordisk Foundation has given a grant of DKK 54.5 million to the ODIN project.
Treatment of non-alcoholic fatty liver disease
Professor Kjems’ project falls into the category of non-alcoholic fatty liver disease. At the moment, a liver biopsy is the only reliable diagnostic approach, but it is an invasive and potentially dangerous procedure. Professor Kjems’ project aims to create a new, reliable, and less dangerous procedure to arrive at a diagnosis.
The project will focus on identifying novel biomarkers in the blood of patients with non-alcoholic fatty liver disease by using a new technology based on an approach named APTASHAPE. This method identifies changes in the protein composition of the blood during onset, development, and treatment of the disease.